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Mechanisms of vascular damage in systemic sclerosis
Abstract
Although being classified as autoimmune connective tissue disease, dominant components of the
pathophysiology of systemic sclerosis (SSc) consists of mechanisms of vascular damage, which can
occur early in the course of the disease. Amongst them are abnormal vasoreactivity, hypoxia,
insufficient neoangiogenesis and direct damage of vascular and perivascular cells. They result in a
decreased capillary blood flow, and subsequently in clinically overt symptoms such as Raynaud's
syndrome and fingertip ulcers. In addition, in active disease vascular pathology can affect various other
organs, predominantly the lung, the kidney, the heart but also the gastrointestinal tract. Vascular
pathology contributes also significantly to overall morbidity and mortality in SSc patients and reduces
life expectancy by at least a decade. Fortunately, molecular biology has revealed a number of underlying
pathways on the cellular and subcellular levels, including key factors of the aberrant function of
(peri)vascular cells and autoimmune effector cells, the dysregulation of vasoconstrictive molecules and
their receptors, the upregulation of intracellular signaling kinases and the altered balance of
hypoxia-induced vascular growth factors. This increasing knowledge of vascular pathology in SSc has
also resulted in novel therapeutic approaches ranging from endothelin antagonists to application of
progenitor cells to counteract this aberrant vascular pathology and to support the repair of the
dysfunctional vasculature.
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Abstract 
 
Although being classified as autoimmune connective tissue disease, dominant 
components of the pathophysiology of systemic sclerosis (SSc) consist of 
mechanisms of vascular damage, which can occur early in the course of the 
disease. Amongst them are abnormal vasoreactivity, hypoxia, insufficient 
neoangiogenesis and direct damage of vascular and perivascular cells. They 
result in a decreased capillary blood flow, and subsequently in clinically overt 
symptoms such as Raynauds syndrome and finger tip ulcers. In addition, in 
active disease vascular pathology can affect various other organs, 
predominantly the lung, the kidney, the heart but also the gastrointestinal tract. 
Vascular pathology contributes also significantly to overall morbidity and 
mortality in SSc patients and reduces life expectancy by at least a decade. 
Fortunately, molecular biology has revealed a number of underlying pathways 
on the cellular and subcellular level including key factors of the aberrant 
function of (peri)vascular cells and autoimmune effector cells, the dysregulation 
of vasoconstrictive molecules and their receptors, the upregulation of 
intracellular signaling kinases and the altered balance of hypoxia-induced 
vascular growth factors. This increasing knowledge of vascular pathology in 
SSc has also resulted in novel therapeutic approaches ranging from endothelin 
antagonists to application of progenitor cells to counteract this aberrant vascular 
pathology and to support the repair of the dysfunctional vasculature. 
Introduction 
 
One of the early hallmarks of SSc is Raynaud`s phenomenon and the reduced 
density of capillaries in the skin and their unique phenotype, especially the so 
called megacapillaries. These phenomena indicate both an insufficient 
vasodilative capacity to vasoconstrictive stimuli, e.g. cold, hypoxia or 
vasoconstrictive molecules such as endothelin-1, as well as a dysfunction in 
angiogenesis and vascular repair. This dysregulation of angiogenesis is 
occurring early in the course of the disease (1,2) and is paralleled by other 
pathogenic processes including fibrosis as well as cellular and humoral 
autoimmunity, which amplifies this dysregulated system in a vicious circle. 
Some of these mechanisms are reflected by biomarkers, although they do not 
yet allow an exact prognosis (3). 
 
Of note, although not yet being examined in detail, it is most likely that this overt 
vascular pathology is also taking place in other organs and compartments of the 
affected patient. In the era of high-resolution computed tomography, these 
subtle changes can already been observed in early stages of the disease. 
Therefore, it is of utmost interest to add more pieces to this puzzle to facilitate 
the development of improved therapeutic regimen, which will not only have an 
impact on vascular pathology but also on overall outcome of the SSc patient. 
 
Clinical implications of vascular damage 
 
In the largest recent clinical data collection of SSc patients (4,5), various 
aspects illustrating the clinical impact of SSc vascular disease could be 
revealed. Both patients with diffuse (d)SSc and limited (l)SSc had an identical 
mean age of onset of about 43 years of the primary sign of vasculopathy, 
Raynauds phenomenon. However, the age at the onset of first non-Raynauds 
manifestation differed between dSSc and lSSc, being 45 years in dSSc and 48 
years in lSSc patients. There was also a longer lag period between the onset of 
Raynauds phenomenon and the next non-Raynauds clinical feature of disease 
in the lSSc (about 5 years) in contrast to the dSSc (about 2 years) patients. In 
both subsets of SSc, patients with an earlier onset of Raynauds phenomenon 
had more often digital ulcers than those with a late onset. The frequency of 
pulmonary vascular disease, specifically pulmonary hypertension (PH) was 
similar in the two subsets, i.e. in 22 % of the dSSc patients and in 21% of the 
lSSc patients. Pulmonary arterial hypertension (PAH, PH in the absence of lung 
fibrosis) was found in 26% of dSSc, and interestingly in 45% of lSSc PH 
patients, indicating a somewhat different pathophysiology in the latter. 
 
However, right heart catheter, which is the gold standard to measure the actual 
pressure indicates a prevalence of lower than 10% of the population. Patients 
with an early onset had significantly less pulmonary fibrosis, pulmonary 
hypertension, diastolic dysfunction and arterial hypertension. Objective cardiac 
complications (conduction block, diastolic dysfunction and left ventricular 
ejection failure) were reported with a similar frequency (20-30%) among the two 
scleroderma subsets, and renal vascular complications (hypertensive renal 
crisis and proteinuria) were more frequent in the dSSc subset. 
 
Genetic and epigenetic factors in vascular pathology 
 
Although not definitively proven by large scale analysis, there are numerous 
indications that genetic abnormalities within the gene sequence of key 
molecules contribute to vascular pathology in SSc. For example, mutational 
analysis on SNPs (single nucleotide polymorphisms) of the hypoxia-induced 
factor (HIF)1A gene has been performed in a cohort of patients including 659 
Caucasian SSc patients and 511 healthy matched controls. Three SNPs 
(rs12434438 A/G, rs1957757 C/T and rs11549465 C/T) were genotyped and 
the results suggests an association of the HIF1A gene with SSc. However, the 
functional tests showed also that rs12434438 is not a functional SNP but it 
could be in disequilibrium linkage with another variant which carries the 
susceptibility to SSc (6). Polymorphisms of genes which regulate endothelial 
cell plasticity and functions have been previously shown to be associated with 
the main vascular manifestations of SSc, such as PAH and ischaemic ulcers 
(7,8). 
 
In addition, similar to other rheumatic diseases, epigenetic modifications most 
likely contribute to the alteration in the posttranslational process of vasoactive 
molecules operative in the pathogenesis of SSc. The term epigenetics refers to 
chromatin-based pathways important in the regulation of gene expression and 
includes three different but interfering mechanisms: DNA methylation, histone 
alteration, and RNA-dependent modifcations. For example, in vascular 
pathophysiology, endothelial nitric oxide synthase has been attributed to 
specific DNA methylation and histone posttranslational modifications. Other 
groups have examined chromatin-based mechanisms in endothelium-restricted 
genes including von Willebrandt factor, Notch4 and EPHB4 (9). More recently, it 
could be shown that expression of methylation-related factors such as Dnmt1 
are involved in the development of a distinct scleroderma phenotype (10). 
 
In SSc, epigenetic mechanisms can modulate fibrosis. When examining the 
effects of DNA methyltransferase and histone deacetylase inhibitors on collagen 
expression and the level of epigenetic mediators in fibroblasts, it could be 
shown that the methylation status of the FLI1 promoter determined the collagen 
production. Vice versa, the addition of epigenetic inhibitors to cell cultures 
normalized collagen expression. In these experiments, collagen synthesis was 
specifically linked to the epigenetic repression and the methylation status of the 
collagen suppressor gene FLI1 and its promoter (11). At the past annual 
meeting of the American College of Rheumatology, the same group presented 
an additional epigenetic repression n the bone morphogenetic protein II in SSc 
endothelial cells (EC), which resulted in an increased sensitivity of the EC to 
apoptotic signals. In the affected cells, DNA methylation and the histone 
deacetylation was found to be the underlying cause for this epigenetic 
modification. When examining the profibrotic pathways in SSc fibroblasts 
histone deacetylase 7 (HDAC7) repression appears also to be involved in 
epigenetic modifications. It could also be shown that, in contrast to the negative 
effects of trichostatin A on the progression of SSc via up-regulation of 
CTGF/CCN2 and ICAM-1, silencing of HDAC7 had no influence on the 
expression of these genes, which resulted in the idea of HDAC7 being a target 
for epigenetic modulation in SSc patients (12). Of note, trichostatin A prevents 
the accumulation of extracellular matrix in a mouse model of bleomycin-induced 
skin fibrosis (13) 
 
Mechanisms of dysfunctional angio- and vasculogenesis 
 
As illustrated in Figure 1, the process of new blood vessel formation, 
angiogenesis, requires the adequate balance between endogenous stimulators 
and inhibitors, which induce and inhibit blood vessel growth. Angiogenesis 
consists of a sequence of evolutionary highly regulated events. In healthy 
individuals, proangiogenic stimuli activate EC, which release proteolytic 
enzymes that degrade the basement membrane and the perivascular 
extracellular matrix. Thereafter, EC proliferate and migrate into the perivascular 
area. After forming primary small new vessels, the following lumenation of these 
primary sprouts results in capillary loops, followed by synthesis of a new 
basement membrane and subsequently in blood vessel maturation. In SSc, a 
number of these sequential steps have revealed to been altered and contribute 
to its pathophysiology (14-16). In addition, the expression of the angiogenic 
inhibitor endostatin has been suggested to be associated with the presence of 
giant capillaries in nailfold capillaroscopy. 
 
Although persisting hypoxia, should be a major stimulus for angiogenesis, 
sufficient angiogenesis does not occur in SSc patients despite severe tissue 
hypoxia (15,16). Most likely, this is based on an insufficient response to the 
elevated levels of VEGF in serum and tissue. VEGF controls several steps of 
angiogenesis, increases the vascular permeability, stimulates the migration and 
proliferation of ECs and induces tube formation (17). Serum levels of VEGF 
correlate also with the development of fingertip ulcers. However, data indicate 
that VEGF still can exert protective effects in SSc patients, if the levels of VEGF 
exceed an individual threshold. A reason for the ineffectiveness of VEGF could 
be that the time being close to the active angiogenic compartment is too short, 
resulting in instable vessels. Vice versa, an extended exposure to VEGF may 
have also negative effects by fusing by immature microvessels in an 
uncontrolled manner resulting in a chaotic vessel network with giant capillaries. 
 
Moreover, in experimental settings, isolated microvascular EC from SSc 
patients show an impaired response to VEGF and other growth factors (18,19). 
Moreover, the CXC chemokine stromal cell-derived factor 1 (SDF-1/CXCL12) 
and its receptor CXCR4 regulate specific steps in new vessel formation. It was 
recently demonstrated an altered expression of both SDF-1 and CXCR4 in skin 
and microvascular ECs from patients with SSc, suggesting an involvement of 
the SDF-1/CXCR4 axis in the pathogenesis of microvascular abnormalities in 
this disease (20). 
 
With respect to vascular matrix pathophysiology, experimental data support the 
idea that the impaired ability to form capillaries in the matrigel assay might be in 
part caused by a matrix metalloproteinase 12 (MMP-12)-mediated cleavage of 
the urokinase-type plasminogen activator receptor (uPAR) isolated 
microvascular ECs from dSSc patients (21) , especially as this urokinase-type 
plasminogen activator (uPa) – uPAR system modulates extracellular matrix 
degradation and the adhesion of EC to the extracellular matrix during 
angiogenesis. Furthermore, cleaved uPAR in SSc microvascular ECs results in 
loss of an integrin-mediated uPAR connection with the actin cytoskeleton which 
accounts for loss of motility and angiogenesis of these cells (22). 
 
In contrast to angiogenesis, vasculogenesis includes the formation of new 
vessels by circulating EPCs, which can occur without preexisting vessels. The 
process is initiated by a release of EPCs from the bone marrow. Initial triggers 
are cytokines and angiogenic growth factors, including again VEGF, but also 
other growth factors such as GM-CSF. Besides insufficient angiogenesis, 
defective vasculogenesis with altered numbers and functional defects of EPCs 
might also contribute to the vascular pathogenesis of SSc. The initial study 
suggested a profound decrease of circulating EPCs, whereas subsequent 
studies found increased numbers of EPCs in patients with SSc (14,23). 
Scleroderma serum-induced EPC apoptosis was demonstrated in a recent 
study, and this may account, at least in part, for the decreased circulating EPC 
levels in scleroderma patients (24). 
 
Furthermore, bone marrow–derived mesenchymal stem cells (MSCs) from SSc 
patients have been examined to determine whether endothelial differentiation of 
these cells is altered following vascular damage, which may explain the 
impaired vascular repair processes (25), and recent data indicate that 
transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma 
serum-induced apoptosis in endothelial progenitor cells (24). 
 
Vasoactive Molecules 
 
Amongst several others, specifically endothelin-1 (ET-1) plays a significant role 
in SSc vascular pathology. Endothelin has been shown to be an effector 
downstream molecule for several growth factors known to be involved in 
vascular and fibrotic diseases, e.g. transforming growth factor- (TGF-). TGF- 
is not only able to induce the expression numerous profibrotic genes, including 
type I collagen, fibronectin, and CTGF/CCN2, but also to contract a collagen gel 
matrix, all these pathways depended strongly on ET-1 (26, 27). 
 
Three isoforms of endothelin, ET-1, ET-2 and ET-3, have been identified so far. 
Their vasoconstrictive effect is more than 100-fold stronger than that of 
noradrenalin. ET-1 is synthesized by ECs as pre-pro-ET-1. This inactive 
precursor is cleaved in two steps, first into pre-ET-1 and then into active 
endothelin. It triggers vasoconstriction, upregulation of VEGF as well as 
vascular remodelling in combination with other cytokines and growth factors, 
e.g. PDGF. ET-1 binds to the endothelin receptor type B (ETB), which, among 
other effects, also regulates ET-1 synthesis. The primary vasoconstrictive effect 
of ET-1 is mediated by the endothelin rector type A (ETA) which is expressed on 
smooth muscle cells of the vascular wall. Therefore, its effects are primarily 
local, and only small amounts are released into the blood stream. From a 
therapeutic point of view, the interaction of ET-1 and its receptor ETA represents 
an attractive target for pharmacologic interventions in SSc (28). 
 
Of note, ET-1 can also exert some proangiogenic effects – even independent of 
inflammation - as shown in the rat corneal bioassay (29), and the matrigel plug 
model (30). In combination with VEGF, ET-1 promotes capillary growth and 
activates the hypoxia response pathway, which also leads to VEGF expression 
and angiogenesis. Additionally, ET-1 may trigger angiogenesis by stimulating 
the production of nitric oxide and matrix metalloproteinase (MMP)-2. However, 
these potentially beneficial effects have not shown to be operative in SSc in an 
adequate manner and do not appear to outweigh its intensive vasoconstrictive 
effects (31). 
 
Direct vasotoxic effects of the immune system – Pathogenic 
autoantibodies 
 
The „traditional“ role of autoantibodies in the pathophysiology of autoimmune 
diseases is the aberrant cellular damage or complement activation by molecular 
mimicry. On the other hand, an increasing body of data indicates that 
autoantibodies can also play an active functional role in pathophysiology (32). 
One of the most important examples in SSc is the presence of agonistic 
profibrotic autoantibodies against the PDGF receptor (33), which not only 
appears to be relevant for matrix formation but also for vascular pathology. The 
direct stimulation with anti-PDGF antibodies results – similar to hypoxic effects 
– in a tyrosine phosphorylation and an upregulation of the Ha-Ras-ERK1/2 
pathway and vasculotoxic reactive oxygen species. In addition, there are 
indications that the number of stimulatory autoantibodies in SSc is even larger 
as expected as it could be shown that not only anti-fibroblast antibodies exist 
that upregulate profibrotic chemokines but also antibodies directly involved in 
vascular pathology such as angiotensin II-receptor type 1 and the endothelin 
receptor type A, which contribute to pulmonary vascular pathology via 
intracellular ERK activation (34-36). 
 
Direct effects on vascular cells – endothelial cell apoptosis 
 
The attempt to support angiogenesis by enhanced -but still deficient- VEGF 
synthesis is paralleled by the finding of an increased activation but also 
apoptosis of EC, which is illustrated on a molecular level by serum markers 
including endothelin-1, sICAM-1, sVCAM-1, thrombomodulin and von-
Willebrand factor (37,38). In addition, nailfold capillary microscopy illustrates 
these alterations by a capillary network with reduced density of capillaries, 
microhemorrhages, giant capillaries and bushy capillaries, with the latter 
reflecting the insufficient attempts of angiogenesis. When examining on a 
cellular level, a multiplication of the basal membrane of microvascular ECs has 
been observed as a marker for EC damage (39). In addition, endothelial cell 
injury can also be triggered by granzymes, endothelial cell–specific 
autoantibodies, vasculotropic viruses, inflammatory cytokines, or reactive 
oxygen radicals generated during ischemia/reperfusion. In in vivo experimental 
approaches using a SSc-like animal model, it could be shown that ECs undergo 
apoptosis before inflammatory infiltrates or accumulation of extracellular matrix 
occur (40). Most likely, this process is further enhanced by anti-endothelial cell 
antibodies as outlined above. 
 
Perivascular alterations 
 
Adjacent to the different layers of the affected microvessel are cells of 
mesenchymal origin, the so called pericytes or perivascular fibroblasts, which 
most likely also contribute to vascular pathology. For example, VEGF appears 
to affect pericytes and is produced by these cells, especially in the more severe 
forms of SSc (41). Platelet growth factor (PDGF), also a potent inducer of 
angiogenesis is found in the vessel wall and deposited in the perivascular 
matrix (42). 
 
It is also known from other fields of research (43) that perivascular fibrosis can 
be triggered by pericytes. Using a transgenic reporter mouse model for renal 
disease expressing enhanced green fluorescent protein (GFP) under the 
regulation of a collagen type I promoter, it could be shown that these pericytes 
can generate collagen type I in the fibrotic kidney. In addition, circulating 
fibrocytes were also recruited to the fibrotic kidney, but these fibrocytes did not 
contribute to interstitial fibrosis. Instead, using kinetic modeling and time course 
microscopy, the pericytes were found to be the major source of interstitial 
myofibroblasts. The latter have been found to express the chemokine receptor 
CCL2/CCR2 in early SSc, which most likely contributes to the initial 
inflammation observed adjacent to the dysfunctional microvasculature (44). 
Thus, it can be speculated that the different components of a injured vessels or 
vascular factors can contribute to the observed perivascular fibrosis. 
 
Along this line, interfering with myofibroblast-dependent vascular remodelling, it 
has been speculated that statins could have a beneficial effect on SSc 
vasculopathy (45). Although not confirmed in all patient cohorts (46), this idea is 
supported by the finding that endothelial dysfunction appears also to be a 
trigger for atherosclerosis in SSc (47). When endothelium-dependent, flow-
mediated dilation was compared to endothelium-independent, nitroglycerin-
mediated dilation of the brachial artery in SSc patients, an impairment of 
endothelium-dependent vasodilatation indicated by low flow-mediated dilation in 
SSc could be found. This was accompanied by carotid atherosclerosis after 
longer disease duration and at higher ages of SSc patients. 
 
Specific Vascular Organ Pathophysiology 
 
Lung 
 
Aside digital ischemia, pulmonary arterial hypertension (PAH) is the most 
prominent problem in SSc-associated pathology (4,5,48). In normal individuals, 
vasoactive molecules produced from endothelial cells adapt the pulmonary 
vascular smooth muscle cell tone to the actual needs of the organism and keep 
the smooth muscle in a state of relaxation. In PAH, the increased pulmonary 
vascular reactivity and abnormal vasoconstriction has been attributed to 
dysfunctional endothelial cell integrity. Similar to the pathophysiology observed 
in digital vessels in SSc, the dysfunctional endothelial cells in PAH are 
associated with an increased production of vasoconstrictor mediators such as 
thromboxane A2, decreased synthesis of prostacyclin and nitric oxide, and 
uncontrolled proliferation (49). This intimal proliferation can even progress to an 
almost complete occlusion of the pulmonary arterioles (50). Progression of PAH 
and remodelling of the (peri)vascular structures are accompanied by impaired 
EC metabolism characterized by a dominance of vasoconstrictive and 
proliferative mediators and a decrease in vasodilative and antiproliferative 
mediators (49). Aside the clinical marker of a decreased DLCO/VA ratio, the 
extent of pulmonal involvement and the level of damage appears to be nicely 
reflected by the levels of NT-proBNP (51). 
 
Of note, PAH and Raynauds syndrome share numerous similarities, not only on 
a clinical level with a substantial number of patients suffering both from 
Raynauds syndrome and PAH (4,5) but also on a molecular level as both 
entities are characterized by endothelial dysfunction with reduced NO release 
and increased plasma levels of endothelin. Some authors even regard the 
severity of Raynauds syndrome as risk factor for pulmonary hypertension. 
Along this line, recurrent contractions and vasospasms of the small pulmonary 
arteries are thought to result in a change in prostanoid metabolism and 
subsequent in the development of pulmonary arterial hypertension (52,53), 
although not all experimental settings support this idea (54,55). However, 
patients with systemic sclerosis and Raynaud- syndrome exhibit a concurrent 
pulmonary vascular dysfunction as demonstrated by an enhanced pulmonary 
vasoconstriction during exercise and stress (56). 
 
Kidney 
 
The pathogenic mechanisms underlying scleroderma renal crisis involve also 
various vascular alterations including intimal thickening of the renal interlobular 
and arcuate arteries, most likely a result of endothelial cell injury. In addition, 
epithelial-to-mesenchymal transdifferentiation and fibrosis in the glomerular and 
tubulointerstitial compartments, and dysregulation of endothelin-1 (ET-1) 
receptor expression, contribute also to renal vascular disease. In detail, the 
decreased renal perfusion results from narrowing of arterial vessels, leading to 
hyperplasia of the juxtaglomerular apparatus and increased renin release. 
However, pathological changes can also be found in the renal vasculature of 
SSc patients without renal crisis, and neither biopsy findings nor plasma renin 
activity can accurately predict the occurrence of SRC but other events such as 
hyperreninaemia could also trigger the acute onset and rapid progression of 
renal failure (57). 
 
Gastrointestinal tract 
 
Mirroring the cutaneous teleangiectasias especially in lSSc, in the 
gastrointestinal tract similar abnormalities can be observed, which are termed 
water melon stomach. These small vessel are vulnerable to mechanical 
irritation and contribute to anemia in these patients. In addition, vasoreactive 
molecules such as endothelin can also be found in full-thickness surgical 
samples (58), accompanied by a generalised fibrosis in the intestinal gastric 
wall, perivascular and around proliferating smooth muscle cells (59). 
 
The lymphocytes infiltrating SSc gastric specimens and therefore contributing to 
vascular pathology and fibrosis, strongly expressed the adhesion molecules 
VLA-4, LFA-1 and ICAM-1. Furthermore, ECs showed corresponding surface 
activation with strong expression of VCAM-1 and ICAM-1, suggesting a pro-
adhesive phenotype favouring a massive strong transendothelial migration of 
inflammatory cells. However, using immunohistology for the pan-endothelial 
marker CD31 that facilitates selective staining of blood vessels, no significant 
difference in microvascular density was observed between SSc and control 
gastric biopsy samples. Furthermore, weak or no VEGF expression was 
detected in both SSc and control specimens. These data suggest a distinct but 
somewhat different pathology of the microvasculature in the intestinal tract (60). 
 
Clinical Implications – Counteracting Vasoconstriction 
 
As summarized in Figure 2, the abovementioned complex underlying 
mechanisms of SSc vasculopathy provides numerous targets for therapeutic 
intervention, both on the vasodilative side as well as by inhibition of 
vasoconstriction and vascular remodeling. Based on the published data, these 
strategies have already been evaluated by a group of experts in a Delphi 
process/metaanalysis approach (61). To improve vascular perfusion, especially 
with respect to digital ischemia, the data indicate that nifedipine and i.v. iloprost 
reduce the frequency and severity of SSc-related Raynauds phenomenon (RP) 
attacks. Therefore, dihydropiridine-type calcium channel blockers, usually oral 
nifedipine, should be considered for first-line therapy for SSc-related RP, and 
intravenous iloprost, or other available i.v. prostanoids, should be considered for 
severe SSc-related RP. 
 
In addition, two controlled clinical trials indicate that intravenous prostanoids 
(particularly i.v. iloprost) are efficacious in healing digital ulcers (DU) in patients 
with SSc. Intravenous prostanoids (in particular iloprost) should therefore be 
considered in the treatment of active DU in patients with SSc. With respect to 
counteracting ET-1, which exerts its effects via the ETA and ETB receptor 
subtypes, clinical data have shown that the oral, dual ET-1 receptor antagonist, 
bosentan, has beneficial effects in SSc patients with respect to PAH and DUs. 
However, bosentan has no proven efficacy in the treatment of active DU in SSc 
patients, but in protecting from the development of new ulcers. Thus, bosentan 
should be considered in diffuse SSc (dSSc) with multiple DU, after failure of 
calcium channel blockers and, usually, prostanoid therapy (61) in a preventive 
strategy. 
 
Moreover, as two high quality RCTs indicate that bosentan improves exercise 
capacity, functional class and some hemodynamic measures in pulmonary 
arterial hypertension (PAH), bosentan should be strongly considered to treat 
SSc-related PAH (SSc-PAH). Numerous trials indicate also that sitaxentan and 
ambrisentan can improve pulmonary arterial hypertension - for the latter this 
has been shown in the ARIES studies 1 and 2 (62). Sildenafil also improves 
exercise capacity, functional class and some hemodynamic measures in PAH, 
supporting the recommendation that sitaxentan, ambrisentan and sildenafil may 
also be considered to treat SSc-PAH. However, several challenges for this 
dominating sequelae still remain to be solved in the future (63-65). With respect 
to the significant impact on morbidity and despite the lack of RCTs, experts are 
of the opinion that angiotensin converting enzyme inhibitors (ACEi) should be 
used in the treatment of scleroderma renal crisis. 
 Clinical Implications – Supporting Repair 
 
Autologous stem cells and progenitor cells are theoretically an ideal tool to 
counteract and repair dysfunctional cells and tissues throughout the human 
body, given the fact that the underlying pathophysiology is known and/or the 
applied stem/progenitor cells home to the sites affected by the disease. In SSc, 
endothelial progenitor cells (EPC) could be such a therapeutic approach (23), 
as it has been shown that there is a lack of EPCs in SSc when compared to 
healthy individuals and lower EPC levels are also associated with a higher 
number of digital ulcers and a more severe course of the disease. One step 
further –similar to the therapeutic concept of implantation of hematopoietic stem 
cells in cardiovascular disease and in thrombangitis obliterans (66) - resulted 
the multilocular implantation of bone marrow-derived stem cells in the palms or 
the plantar region in an improvement of the symptoms in severe Raynauds 
syndrome within few weeks, which could also be visualized in arteriography 
(67). However, the mode of action of this approach in this study still needs to be 
evaluated in detail, as only in one patient neoangiogenesis could be confirmed. 
However, when comparing stem cell transplantation to conventional 
cyclophosphamide therapy, the effect on angiogenesis appears to be 
significant. A recent study showed that after hematopoietic stem cell 
transplantation, in beforehand avascular regions of the nailbed, a new formation 
of vessels, e.g. giant capillaries, could be observed (68). 
 
Summary 
 
Both high resolution molecular analysis as well as extensive data collection in 
nation-to-worldwide patient cohorts has provided substantial advance in 
knowledge of vascular pathology in SSc patients. Based on this progress, 
several novel ideas have been generated that have already or will be implicated 
for the diagnosis, monitoring or treatment of the patients suffering from this 
debilitating disease in the near future (69). 
Figures 
Figure 1: Angiogenic and angiostatic factors in SSc vasculopathy (modified 
from 31). 
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Figure 2: Potential therapeutic options in SSc vascular disease 
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